0.1%Tacrolimus (FK506) in the treatment of sjogren's syndrome clinical efficacy evaluation

Trial Profile

0.1%Tacrolimus (FK506) in the treatment of sjogren's syndrome clinical efficacy evaluation

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2016

At a glance

  • Drugs Tacrolimus (Primary) ; Hyaluronic acid
  • Indications Sjogren's syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top